Compare Goldman Sachs Physical Gold ETF (AAAU) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs Viatris Inc — how do they compare? Goldman Sachs Physical Gold ETF trades at $43.61, while Viatris Inc trades at $16.3 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Goldman Sachs Physical Gold ETF pays none, and Viatris Inc is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | VTRS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $17.86 |
52-Week Low | $32.74 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused stock, trades at $43.73, up 1.06% with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and geopolitical tensions, with spot gold reaching $4,438/oz (Kitco, 2026-08-12). Financial ratios are unavailable, limiting fundamental clarity.
The outlook is mixed: technical momentum supports near-term gains, but overbought RSI levels suggest caution. Gold's appeal as a safe-haven asset amid economic uncertainty offers upside, yet reliance on commodity prices and absent financial metrics pose risks for stock investors.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
